Investing.com - Financial Markets Worldwide

Agilent and Oxford BioDynamics to showcase 3D genomics platform

Published 17/07/2025, 07:10
Agilent and Oxford BioDynamics to showcase 3D genomics platform
A
-0.43%
OBD
-21.05%

OXFORD - Agilent Technologies (NYSE:A) and Oxford BioDynamics (AIM:OBD) will jointly present their collaborative 3D genomics platform in a GenomeWeb webinar scheduled for Thursday evening, according to a press release statement from Oxford BioDynamics.

The presentation will demonstrate how Oxford BioDynamics’ EpiSwitch Array Platform utilizes Agilent’s SureScan microarray technology to examine 3D genome architecture elements associated with specific diseases.

During the webinar, Oxford BioDynamics’ Chief Scientific Officer Alexandre Akoulitchev will present applications of the technology, including the company’s prostate cancer detection test (EpiSwitch PSE) and its Multi-Cancer Early Detection test for canines (EpiSwitch SCB). Valentina Maran, Senior Product Manager at Agilent, will discuss Agilent’s role in the technology.

The EpiSwitch Explorer Array Kit, built on Agilent’s SureScan platform, allows researchers to examine nearly one million chromosome conformations across the genome for biomarker discovery.

Thomas Guiel, COO of Oxford Biodynamics, noted in the release that the companies have collaborated for several years to develop custom 3D genomics arrays across multiple configurations and species.

"This strategic collaboration has been pivotal in the advancement of our EpiSwitch Platform, supporting high-resolution, rapid, and reproducible detection of disease-specific 3D genomic biomarkers from blood samples," Guiel stated.

The webinar aims to explain 3D genomics as a biological phenomenon, demonstrate the application of the EpiSwitch Explorer Array, and discuss real-world examples of the technology in clinical settings.

The online event is scheduled for 6:00 pm BST today, July 17, 2025, and is being hosted by GenomeWeb with sponsorship from Agilent Technologies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.